Premium
Ranibizumab for the treatment of exudative age‐related macular degeneration associated with retinal pigment epithelial detachment
Author(s) -
ZIYATDINOVA O,
SAFIULLINA L
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.3217.x
Subject(s) - ranibizumab , macular degeneration , medicine , ophthalmology , visual acuity , retinal detachment , retinal pigment epithelium , retinal , exudative age related macular degeneration , lesion , retina , surgery , chemotherapy , bevacizumab , biology , neuroscience
Purpose To evaluate the efficacy of intravitreal ranibizumab in eyes with exudative age‐related macular degeneration associated with retinal pigment epithelial detachment. Methods In this retrospective case series, patients with active exudative age‐related macular degeneration associated with retinal pigment epithelial detachment were treated by repeated injections of intravitreal ranibizumab. The outcome measures were best‐corrected visual acuity and the signs of lesion activity, as evaluated by optical coherence tomography. Results Fifteen eyes of 15 patients were followed‐up for a median of 6 months (range, 3‐12 months). The median number of injections was 3 (range, 1‐6). The best‐corrected visual acuity improved in 8 eyes (53,4%), remained stable in 5 (33,3%), and decreased in 2 (13,3%). Conclusion Intravitreal ranibizumab was effective in improving or stabilizing vision and resulting in a quiescent lesion in the majority of patients with exudative age‐related macular degeneration associated with retinal pigment epithelial detachment. The functional results were apparently better in eyes without foveal involvement by the retinal pigment epithelial detachment..